Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:52:27.455Z.
Calculation as of: 2026-10-06T15:52:27.455Z.
Quote observation: 2026-10-06T15:49:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.22B
EV/Sales Ratio
1.22x
TTM Avg
1.20x
3Y Avg
1.00x
5Y Avg
1.05x
Market Cap
$1.22B
EV/Sales Ratio
3.80x
TTM Avg
4.64x
3Y Avg
5.92x
5Y Avg
9.62x
Market Cap
$1.16B
EV/Sales Ratio
23.02x
TTM Avg
24.63x
3Y Avg
10.61x
5Y Avg
10.20x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.24B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.23B | 3.26x | 3.34x | 3.78x | 3.78x |
| Cronos Group Inc. (CRON)vs › | $1.23B | 3.38x | 1.73x | 1.52x | 2.69x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 1.22x | 1.20x | 1.00x | 1.05x |
| MannKind Corporation (MNKD)vs › | $1.22B | 3.80x | 4.64x | 5.92x | 9.62x |
| Kardigan, Inc. (KARD)vs › | $1.30B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.16B | 23.02x | 24.63x | 10.61x | 10.20x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 1.78x | 1.60x | 2.60x | 4.51x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
